Docoh
Loading...

ABEO Abeona Therapeutics

Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing gene and cell therapies for serious diseases. Abeona's clinical programs include EB-101, its autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa in Phase 3 development, as well as ABO-102 and ABO-101, novel AAV-based gene therapies for Sanfilippo syndrome types A and B (MPS IIIA and MPS IIIB), respectively, in Phase 1/2 development. The Company's portfolio also features AAV-based gene therapies for ophthalmic diseases with high unmet medical needs. Abeona's novel, next-generation AIM™ capsids have shown potential to improve tropism profiles for a variety of devastating diseases. Abeona's fully functional, gene and cell therapy GMP manufacturing facility produces EB-101 for the pivotal Phase 3 VIITAL™ study and is capable of clinical and commercial production of AAV-based gene therapies.

Company profile

Ticker
ABEO
Exchange
CEO
Joao Siffert
Employees
Incorporated
Location
Fiscal year end
Former names
ACCESS PHARMACEUTICALS INC, CHEMEX PHARMACEUTICALS INC, PLASMATECH BIOPHARMACEUTICALS INC
SEC CIK
IRS number
830221517

ABEO stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

28 Jul 21
2 Aug 21
31 Dec 21
Quarter (USD)
Jun 21 Mar 21 Dec 20 Sep 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 28.15M 28.15M 28.15M 28.15M 28.15M 28.15M
Cash burn (monthly) (positive/no burn) (positive/no burn) 4.57M 4.09M 3.83M 3.12M
Cash used (since last report) n/a n/a 5.11M 4.57M 4.28M 3.48M
Cash remaining n/a n/a 23.04M 23.59M 23.87M 24.67M
Runway (months of cash) n/a n/a 5.0 5.8 6.2 7.9

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
1 Jun 21 Vishwas Seshadri Common stock Grant Aquire A No No 0 100,000 0 300,000
1 Jun 21 Vishwas Seshadri Common stock Grant Aquire A No No 0 200,000 0 200,000
1 Jun 21 Vishwas Seshadri Stock Option Common Stock Grant Aquire A No No 1.71 400,000 684K 400,000
25 May 21 Rouhandeh Steven H Common Stock Grant Aquire A No No 0 38,590 0 533,590
25 May 21 Rouhandeh Steven H Stock Option Common Stock Grant Aquire A No No 1.49 49,084 73.14K 49,084
25 May 21 Leila Alland Common Stock Grant Aquire A No No 0 77,181 0 77,181
25 May 21 Leila Alland Stock Option Common Stock Grant Aquire A No No 1.49 98,168 146.27K 98,168
25 May 21 Mark Alvino Common Stock Grant Aquire A No No 0 77,181 0 82,181
25 May 21 Mark Alvino Stock Option Common Stock Grant Aquire A No No 1.49 98,168 146.27K 98,168

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

13F holders
Current Prev Q Change
Total holders 0 0
Opened positions 0 0
Closed positions 0 0
Increased positions 0 0
Reduced positions 0 0
13F shares
Current Prev Q Change
Total value 0 0
Total shares 0 0
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
Largest transactions
Shares Bought/sold Change
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: advocating, agreeing, alleviate, argued, assign, ATM, authorizing, behalf, binding, card, choose, confidential, conflict, creation, credit, diligence, embodying, extinguishment, factor, foregoing, hand, injunction, invalidity, invention, inventorship, joint, July, launch, law, lowest, minimum, notice, permanent, permit, prevent, priority, relevant, settlement, valid, yearly
Removed: assessment, capability, consistent, detail, entity, legal, measuring, obtained, professional, QUALITATIVE, QUANTITATIVE, refer